An inflection point in gene discovery efforts for neurodegenerative diseases: From syndromic diagnoses toward endophenotypes and the epigenome

JAMA Neurology

Volumn 70, Issue 6, 2013, Pages 719-726

  De Jager, Philip L ^a,b,c   Bennett, David A ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ASYMPTOMATIC DISEASE; CHROMATIN STRUCTURE; DEGENERATIVE DISEASE; DNA METHYLATION; ENDOPHENOTYPE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN GENOME; MULTIPLE SCLEROSIS; NEUROIMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 84878777552     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.275     Document Type: Review

References (50)

1. International HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968):789-796. doi:10.1038/nature02168.
2. Abecasis GR, Auton A, Brooks LD, et al; 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56-65. doi:10.1038/nature11632.
3. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68(2):270-281. doi:10.1016/j.neuron.2010.10.013.
4. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009;18(R1):R48-R59. doi:10.1093/hmg/ ddp012.
5. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006;7(9):710-723. doi:10.1038/nrn1971. (Pubitemid 44267495)
6. Ramagopalan SV, Dyment DA, Cader MZ, et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol. 2011;70(6):881-886. doi:10.1002/ana.22678.
7. Vilariño-Güell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011;89(1):162-167. doi:10.1016/j.ajhg.2011. 06.001.
8. Zimprich A, Benet-Pagès A, Struhal W, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011;89(1):168-175. doi:10.1016/j.ajhg.2011.06.008.
9. Bush WS, Sawcer SJ, de Jager PL, et al International Multiple Sclerosis Genetics Consortium (IMSGC). Evidence for polygenic susceptibility to multiple sclerosis: the shape of things to come. Am J Hum Genet. 2010;86(4):621-625. doi: 10.1016/j.ajhg.2010.02.027.
10. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Hum Genet. 2012;90(1):7-24. doi:10.1016/j.ajhg.2011.11.029.
11. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273(5281):1516-1517. (Pubitemid 26301653)
12. De Jager PL, Jia X, Wang J, et al; International MS Genetics Consortium. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009;41(7):776-782. doi: 10.1038/ng.401.
13. Shulman JM,De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol. 2011;6:193-222. doi:10.1146/annurev-pathol- 011110-130242.
14. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368(2):107-116. doi:10.1056/NEJMoa1211103.
15. Guerreiro R, Wojtas A, Bras J, et al Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2):117-127. doi:10.1056/NEJMoa1211851.
16. Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol. 2012;72(4):599-609. doi:10.1002/ana.23654.
17. Buchman AS, Shulman JM, Nag S, et al. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol. 2012;71(2):258-266. doi:10.1002/ana.22588.
18. Bennett DA, De Jager PL, Leurgans SE, Schneider JA. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. Neurology. 2009;72(17):1495-1503. doi:10.1212/WNL.0b013e3181a2e87d.
19. De Jager PL, Shulman JM, Chibnik LB, et al Alzheimer's Disease Neuroimaging Initiative. A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiol Aging. 2012;33(5):1017, e1-e15. doi:10.1016/j.neurobiolaging.2011.09.033.
20. Stein JL, Medland SE, Vasquez AA, et al Alzheimer's Disease Neuroimaging Initiative; EPIGEN Consortium; IMAGEN Consortium; Saguenay Youth Study Group; Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium; Enhancing Neuro Imaging Genetics through Meta-Analysis Consortium. Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet. 2012;44(5):552-561. doi:10.1038/ng.2250.
21. Bis JC, DeCarli C, Smith AV, et al; Enhancing Neuro Imaging Genetics through Meta-Analysis Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. Common variants at 12q14 and 12q24 are associated with hippocampal volume. Nat Genet. 2012;44(5):545-551. doi:10.1038/ng.2237.
22. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106(16):6820-6825. doi:10.1073/pnas.0900345106.
23. Chibnik LB, Shulman JM, Leurgans SE, et al. CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol. 2011;69(3):560-569. doi:10.1002/ana.22277.
24. Elias-Sonnenschein LS, Bertram L, Visser PJ. Relationship between genetic risk factors and markers for Alzheimer's disease pathology. Biomark Med. 2012; 6(4):477-495. doi:10.2217/bmm.12.56.
25. Brouwers N, Van Cauwenberghe C, Engelborghs S, et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/ C4b binding sites. Mol Psychiatry. 2012;17(2):223-233. doi:10.1038/mp.2011. 24.
26. Schjeide BM, Schnack C, Lambert JC, et al. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry. 2011;68(2):207-213. doi:10.1001/archgenpsychiatry.2010.196.
27. Keenan BT, Shulman JM, Chibnik LB, et al Alzheimer's Disease Neuroimaging Initiative. A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline. Hum Mol Genet. 2012;21(10):2377-2388. doi:10.1093/hmg/dds054.
28. Myers AJ, Pittman AM, Zhao AS, et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2007;25(3):561-570. doi:10.1016/j.nbd. 2006.10.018.
29. Xia Z, Liu Q, Berger CT, et al. A 17q12 allele is associated with altered NK cell subsets and function. J Immunol. 2012;188(7):3315-3322. doi:10.4049/jimmunol.1102775.
30. Stranger BE, De Jager PL. Coordinating GWAS results with gene expression in a systems immunologic paradigm in autoimmunity. Curr Opin Immunol. 2012;24(5):544-551. doi:10.1016/j.coi.2012.09.002.
31. Zou F, Chai HS, Younkin CS, et al Alzheimer's Disease Genetics Consortium. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet. 2012;8(6):e1002707. doi:10.1371/journal.pgen.1002707.
32. Webster JA, Gibbs JR, Clarke J, et al NACC-Neuropathology Group. Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet. 2009;84(4):445-458. doi:10.1016/j.ajhg.2009.03.011.
33. Lourdusamy A, Newhouse S, Lunnon K, et al; AddNeuroMed Consortium; Alzheimer's Disease Neuroimaging Initiative. Identification of cis-regulatory variation influencing protein abundance levels in human plasma. Hum Mol Genet. 2012;21(16):3719-3726. doi:10.1093/hmg/dds186.
34. Kauwe JS, Cruchaga C, Mayo K, et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A. 2008;105(23):8050-8054. doi:10.1073/pnas.0801227105. (Pubitemid 351904706)
35. Choy E, Yelensky R, Bonakdar S, et al. Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet. 2008;4(11):e1000287. doi:10.1371/journal.pgen.1000287.
36. Patsopoulos NA, Esposito F, Reischl J, et al; Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011;70(6):897-912. doi:10.1002/ana.22609.
37. Sawcer S, Hellenthal G, Pirinen M, et al International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214-219. doi:10.1038/nature10251.
38. Guerreiro RJ, Hardy J. Alzheimer's disease genetics: lessons to improve disease modelling. Biochem Soc Trans. 2011;39(4):910-916. doi:10.1042/ BST0390910.
39. Mutez E, Larvor L, Leprêtre F, et al. Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol Aging. 2011;32(10):1839-1848. doi:10.1016/j.neurobiolaging.2009.10.016.
40. Kappos L, Freedman MS, Polman CH, et al BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389-397. doi:10.1016/S0140-6736(07) 61194-5. (Pubitemid 47189673)
41. Comi G, Martinelli V, Rodegher M, et al; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503-1511. doi:10.1016/S0140-6736(09)61259-9.
42. Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012;2(10):975-984. doi:10.4155/cli.12.93.
43. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(suppl 3):321-329. doi:10.3233/JAD-2011-0059.
44. Wilson PW, Hoeg JM, D'Agostino RB, et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med. 1997;337(8):516-522. doi:10.1056/NEJM199708213370802. (Pubitemid 27352017)
45. Green RC, Roberts JS, Cupples LA, et al REVEAL Study Group. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009;361(3):245-254. doi:10.1056/NEJMoa0809578.
46. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature. 2007;447(7143):433-440. doi:10.1038/nature05919. (Pubitemid 46816750)
47. Bernstein BE, Stamatoyannopoulos JA, Costello JF, et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol. 2010;28(10):1045-1048. doi: 10.1038/nbt1010-1045.
48. Dunham I, Kundaje A, Aldred SF, et al ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489(7414):57-74. doi:10.1038/nature11247.
49. Ernst J, Kheradpour P, Mikkelsen TS, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature. 2011;473(7345):43-49. doi:10.1038/nature09906.
50. Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common diseaseassociated variation in regulatory DNA. Science. 2012;337(6099):1190- 1195. doi: 10.1126/science.1222794.